Fig. 1

Impact of ASCs, metformin, or combination prophylactic therapy on functional outcomes linked to RISF. A Skin architecture at day 42 post 40Gy irradiation. Local injection of 3 × 10⁶ autologous ASCs (C57BL/6 origin ASCs injected in irradiated C57BL/6 host) on day 1 post-irradiation or 100 mg/kg body weight metformin was injected 3 times a week starting day 1, or a combination of both ASCs and metformin or saline (control) was injected. B and C The degree of leg motion was measured on days 35 (B), and 42 (C) post-irradiation and plotted (n = 8–10 per group). D Skin architecture at day 42 post 40Gy irradiation. Local injection of 3 million allogeneic ASCs (FVB origin ASCs injected in irradiated C57BL/6 host) on day 1 post-irradiation or 100mg/kg body weight metformin was injected 3 times a week starting day 1, or a combination of both ASCs and metformin or saline (control) was injected. E and F The degree of leg motion was measured on days 35 (E), and 42 (F) post-irradiation and plotted (n = 8–10 per group). P value < 0.05 = ^*, < 0.005 = ^**, < 0.0005 = ^***, < 0.00005 = ^****